NCT02585752View on ClinicalTrials.gov

A Study of Expiratory Pressure Modulation in Moderate to Severe COPD Patients - Phase 1b

NATerminatedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

October 1, 2015

Primary Completion Date

September 30, 2017

Study Completion Date

November 24, 2017

Conditions
Chronic Obstructive Pulmonary Disease
Interventions
DEVICE

Noninvasive ventilation

Expiratory pressure modulation

Trial Locations (1)

52074

Universitätsklinikum Aachen, Aachen

Sponsors

Lead Sponsor

ResMed
All Listed Sponsors
lead

ResMed

INDUSTRY

NCT02585752 - A Study of Expiratory Pressure Modulation in Moderate to Severe COPD Patients - Phase 1b | Biotech Hunter | Biotech Hunter